Jon Faiz Kayyem

Filings by Jon Faiz Kayyem span 4 companies, the busiest being GenMark Diagnostics, Inc., Inhibrx Biosciences, Inc. and Inhibrx, Inc. Between 21 January 2016 and 23 September 2026, the trades on record add up to 78 filings.

The open-market side counts 15 purchases for €8.4M alongside 36 sales for €1.2M. Taken together, the purchases exceed the sales by €7.2M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 6 share grants and 5 option exercises. So far in 2026, the count stands at 3 purchases and no sales.

In size, the median ticket on the buying side is €468k. Measured against the company's value, the median purchase equals 0.037% of market capitalisation, across 3 purchases where it is known. 4 out of 14 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 23 September 2026, the filings show an open-market purchase worth €437k in Inhibrx Biosciences, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.